Ginkgolide Dropping Pills belong to the category of National Traditional Chinese Medicine Class 1.2 new drugs in the Drug Registration Management Measures. It is a sequential therapy oral preparation developed on the basis of the already marketed Ginkgolide Injection.
Ginkgolide Dropping Pills and Ginkgolide Injection (National Medical Products Approval No. Z20110035, Jinggelai) ®) The main components are the same, all of which are high-purity ginkgolides, including bilobalide, ginkgolide A, ginkgolide B, ginkgolide C, and ginkgolide J. The total content of terpenoid lactones is over 95%.
Unique drop pill formulation, easy to take, high bioavailability, and rapid onset of action.
The Phase III clinical trial of Ginkgolide Dropping Pills has ended, and production will be declared in 2024. After the product is launched, it is expected to bring a new oral treatment option for ischemic stroke patients with full course applicability and multiple benefits.